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Background: Antipsychotic drugs are considered a trigger factor for autonomic dysregulation, which has been
shown to predict potentially fatal arrhythmias in schizophrenia. However, the dose-dependent effect of
antipsychotic drugs and other psychotropic drugs on autonomic nervous system (ANS) activity remain unclear.
The purpose of this study was to investigate the dose-dependent effect of antipsychotic drugs and other clinical
factors on ANS activity in an adequate sample size of patients with schizophrenia.
Methods: A total of 211 Japanese patients with schizophrenia and 44 healthy subjects participated in this study.
ANS activity was assessed by means of heart rate variability (HRV) power spectral analysis. Antipsychotic drug
treatment and various clinical factors were investigated for each participant. The patient group was categorized into
three subgroups according to daily dose of antipsychotic drug, and HRV was compared between groups.
Results: The results showed significantly decreased low-frequency and high-frequency components of HRV in the
patient group compared to the control group. The high-dose group showed a significantly lower HRV than the
medium-dose group and an even lower HRV than the low-dose group. In addition, a significant association
between HRV and antipsychotic drug dose was identified by multiple regression analysis. HRV was not associated
with age, sex, body mass index, duration of illness, or daily dose of other psychotropic drugs.
Conclusion: These results suggest that antipsychotic drugs exert a significant dose-dependent effect on the extent
of decline in ANS activity, and that optimal antipsychotic medication is required to avoid possible cardiovascular
adverse events in patients with schizophrenia.
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Increased mortality in patients with schizophrenia com-
pared to the general population has been consistently
reported [1-4]. Previous studies have suggested that anti-
psychotic medications are associated with significant
rates of lethal arrhythmias and instances of sudden death
[4-7]. Given that both typical and atypical antipsychotic
drugs affect the autonomic nervous system (ANS) via
neuroleptic effects on various neurotransmitter recep-
tors, antipsychotic drugs are thought to be a trigger* Correspondence: chiaki.kawanishi@gmail.com
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reproduction in any medium, provided the orfactor for autonomic dysregulation. In addition, evidence
now exists for an association between decreased ANS
activity and increased risk of sudden cardiac death [8-12].
Therefore, it is considered important that clinicians assess
ANS activity in patients with schizophrenia treated with
antipsychotic drugs to estimate subclinical signs of adverse
effects.
Decreased ANS activity in schizophrenia has been
reported. Yet, some researchers have suggested an asso-
ciation between low ANS activity and the effects of severity
of schizophrenia instead of the effects of antipsychotic
drugs [13-17]. These researchers report lower ANS activity
in medication-free patients with schizophrenia and lower
ANS activity in patients with schizophrenia with severeal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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decreased ANS activity to medication [18,19]. Those
studies suggest that various antipsychotic drugs, which
have wide-ranging receptor affinity profiles, decrease
parasympathetic nerve activity. However, in those studies,
the sample sizes were relatively small or the authors did
not consider the dose-dependent effect of antipsychotic
drugs on ANS activity or did not assess the influence of
coadministered drugs.
The aim of this study was to investigate the dose-
dependent effect of antipsychotic drugs on ANS activity
in an adequate sample size. We targeted more than 200
patients with schizophrenia under medication for long
periods and investigated various clinical factors, includ-
ing psychotic symptoms, duration of illness, and other
psychotropic drugs, that might affect ANS activity.Methods
Subjects
The study protocol was approved by the Institutional
Review Board of Seishinkai Fujisawa Hospital and was
performed in accordance with the Declaration of Helsinki.
All participants provided written informed consent after
receiving detailed information on the study.
The study included 211 Japanese patients with schizo-
phrenia (166 inpatients and 45 outpatients; 82 men and
129 women; mean ± standard deviation [SD] age 53.8 ±
14.6 years. These patients met diagnostic criteria for
schizophrenia according to the Diagnostic and Statistical
Manual of Mental Disorders [20]. Patients with preexist-
ing diseases known to affect ANS activity were excluded.
The mean score on the Global Assessment of Functioning
Scale [20] (GAF) was 33.7 (SD: 11.7). All of the patients
had been already receiving the standard medication before
the measurement of ANS activity. All given psychotropic
medications on the measurement date of ANS activity,
including antipsychotic, anticholinergic antiparkinsonian,
and anxiolytic drugs, were registered, and doses were
calculated according to standard equivalent conversions
[21] of chlorpromazine, biperiden and diazepam. After the
measurement of ANS activity, we categorized the patient
group into three subgroups according to daily dose of
antipsychotic drug in order to study the dose-dependent
effects of antipsychotic and other psychotropic drugs
on ANS activity. The daily dose in the low-dose group
(63 patients; age 57.0 ± 16.2) was ≤500 mg/day; that in
the medium-dose group (59 patients; age 53.0 ± 14.8)
was 501 to 1000 mg/day; and that in the high-dose
group (89 patients; age 52.1 ± 12.9) was ≥1001 mg/day.
All procedures were carried out as a part of the standard
care.
Control data were obtained from 44 healthy subjects
(14 men and 30 women; mean age 48.4 ± 13.4 years).None of the subjects had a history of physical and/or
psychiatric disorder or were taking medication.
Experimental procedure
All measurements were obtained in the same order be-
tween 9:00 AM and 11:00 AM in a quiet, comfortable
room with minimal arousal stimuli. First, body compos-
ition was measured (DS-320; Tanita, Tokyo, Japan), and
after appropriate skin preparation, subjects were fitted
with electrocardiography (ECG) electrodes and allowed
to rest for at least 20 min before measurements were
taken. After resting, the CM5 lead ECG electrode was
recorded continuously for 5 min with the subject in a
sitting position. During the measurement period, all sub-
jects breathed 15 times per min (0.25 Hz) in synchrony
with a metronome to ensure that variation in heart rate
fluctuation (<0.15 Hz) was respiratory-associated and
not due to another source.
R-R interval power spectral analysis procedure
We used a computer-assisted, 5-min measurement of
resting heart rate variability (HRV) to evaluate ANS ac-
tivity, according to our previous studies [22,23]. The
details of our R-R interval power spectral analysis proce-
dures used have been fully described elsewhere [24]. The
analytic technique for the present investigation has been
applied in basic physiology and clinical research fields,
and its validity and reliability have been confirmed in
our early studies [23-25]. In addition, the results con-
firmed those of previous studies, in which Akselrod
et al. Pagani et al. and Pomeranz et al. [26-28] conducted
experiments on animals or humans with HRV power
spectral analysis [29]. The ECG signal was amplified
(BBA-8321; Bio-Tex, Kyoto, Japan), digitized via a 13-bit
analog-to-digital converter (Daq AD132; Elan, London,
United Kingdom) at a 1024-Hz sampling rate, and stored
sequentially on a hard disk for later analysis. The stored
ECG signal was differentiated, and the QRS spikes and
intervals of the impulses (R-R intervals) were detected.
The R-R interval data were aligned to obtain equally
spaced samples with an effective sampling frequency of
2 Hz and displayed on a computer screen for visual in-
spection [30]. The direct current component and trend
were then completely eliminated with a digital band-
pass filter (0.03–0.4 Hz). After passing the data through
a Hamming-type data window, power spectral analysis
was performed by means of fast Fourier transform on a
consecutive 256-s time series of R-R interval data
obtained during the test. The spectral powers in the fre-
quency domain were quantified by integrating the areas
under the curve for the following respective bandwidth
measurements: low-frequency (LF; 0.03–0.15 Hz) com-
ponent of HRV representing both sympathetic and para-
sympathetic nerve activity; high-frequency (HF; 0.15–0.4
Table 1 Demographic and medication data for all
subjects
Controls (n = 44) Patients (n = 211)
Female/male 30/14 129/82
Age (years) 48.4 ± 13.4 53.8 ± 14.6
Body mass index 23.1 ± 3.6 22.9 ± 4.3
CPZeq*1 (mg) N/A*4 1078.0 ± 882.5
BPDeq*2 (mg) N/A 3.2 ± 1.5
DZPeq*3 (mg) N/A 11.1 ± 7.3
Data are presented as mean ± standard deviation (SD).
*1The daily dose of antipsychotic drug was converted to approximate
chlorpromazine equivalent.
*2The daily dose of anticholinergic antiparkinsonian drug was converted to
approximate biperiden equivalent.
*3The daily dose of anxiolytic drug was converted to approximate diazepam
equivalent.
*4Not available.
Table 2 Comparison of absolute (log) power values of the
frequency bands for low frequency (LF), high frequency
(HF), and LF/HF between patients and controls
lnLF lnHF lnLF/HF
Control group (n = 44) 4.66 ± 0.94 4.25 ± 1.41 0.41 ± 1.15
Patient group (n = 211) 3.50 ± 1.62 3.23 ± 1.60 0.29 ± 1.12
P value <0.001*1 <0.001*2 0.511
Data are presented as mean ± standard deviation (SD).
*1, 2Significant difference (P < 0.05, Student’s t-test).
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parasympathetic nerve activity; total power (TP; 0.03–0.4
Hz) representing overall ANS activity; and LF/HF ratio
representing relative sympathetic nerve activity [26-28].
Statistical analysis
All statistical analyses were performed with SPSS for
Windows Version 11.5 (SPSS, Chicago, IL). We first
assessed group differences in clinical characteristics (age,
sex, and body mass index (BMI)) between patients with
schizophrenia and control subjects with the Student’s
unpaired t-test or the chi-squared test, and we compared
both the LF and HF components of HRV, and the LF/HF
ratio between patients with schizophrenia and control
subjects with the Student’s unpaired t-test. In addition,
we categorized the patient group into three subgroups
according to daily dose of antipsychotic drug. To assess
the difference of ANS activity between groups, variables
were analyzed by analysis of variance (one-way ANOVA),
with both the LF and HF components of the HRV as the
outcomes. Post-hoc comparisons employed the Scheffé’s
test. In addition, for patients with schizophrenia, we ana-
lyzed the influence of clinical factors on ANS activity by
the multiple regression analysis, using both the LF and HF
components of the HRV as dependent variables, and age,
sex, BMI, GAF score, duration of illness, antipsychotic
drug dose (chlorpromazine equivalent: CPZeq [21]), anti-
cholinergic antiparkinsonian drug dose (biperiden equiva-
lent: BPDeq [21]), and anxiolytic drug dose (diazepam
equivalent: DZPeq [21]) as independent variables. Owing
to skewed data, logarithmic transformation was performed
on the absolute units of spectral components of the HRV
before statistical analysis. A value of P < 0.05 was con-
sidered statistically significant.
Results
Comparison of patients with schizophrenia and controls
Demographic and medication data for all subjects are
listed in Table 1. There was a statistically significant differ-
ence in mean age between the schizophrenia group and
the control group (patient: 53.8 ± 14.6; control: 48.4 ±
13.4; P = 0.027). There were no differences in sex or mean
BMI between the two groups. Given antipsychotic drug
dose was 1078.0 ± 882.5 mg/day (CPZeq) for the schizo-
phrenia group. In addition, given anticholinergic antipar-
kinsonian drug dose and given anxiolytic drug dose was
3.2 ± 1.5 mg/day (BPDeq) and 11.1 ± 7.3 mg/day (DZPeq),
respectively. Various antipsychotic drugs were prescribed.
The most common was risperidone (47.5%), followed by
levomepromazine (37.9%) and chlorpromazine (27.5%).
The rate of antipsychotic polypharmacy was 72.0%.
Electrophysiologic results are presented in Table 2. We
confirmed normality of both the LF and HF components
of HRV. Results of the Student’s unpaired t-test showedthat both the LF and HF components of HRV in the
patient group were lower than those in control group
(LF: P < 0.001; HF: P < 0.001). There were no differences
in the LF/HF ratio between the two groups (P = 0.511).Effects of antipsychotic medication on ANS activity in
patients with schizophrenia
We categorized the patient group into three subgroups
according to daily dose of antipsychotic drug (Figure 1).
There were no differences in age, sex, mean BMI or
duration of illness among three groups except for GAF
scores. The high-dose group showed a significantly
lower HRV than the medium-dose group (LF: P = 0.004;
HF: P = 0.01) and an even lower HRV than the low-dose
group (LF: P < 0.001; HF: P < 0.001). The medium-dose
group showed a significantly lower HRV than the
control group (LF: P = 0.02; HF: P = 0.048), as did the
high-dose group (LF: P < 0.001; HF: P < 0.001).Association between ANS activity, psychotropic drug
dose, and other factors
The multiple regression analysis for the schizophrenia
group showed a statistically significant association between
both the LF and HF components of HRV and CPZeq anti-
psychotic drug dose (LF: P = 0.048; HF: P = 0.011) (Table 3).
There was no significant association between the spectral
Figure 1 Comparison of (log) power value of the frequency bands for low frequency (LF) and high frequency (HF) between the three
subgroups of patient group. Lateral bars show mean for each group.
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kinsonian drug dose or DZPeq benzodiazepine anxiolytic
drug dose. There was also no association between the spec-
tral components of HRV and age, sex, BMI, GAF score, or
duration of illness.
Discussion and conclusion
In this study, we found a markedly lower power of both
the LF and HF components of HRV, but not a lower LF/
HF ratio in patients with schizophrenia compared toTable 3 Multiple regression analyses of ANS activity, age,
sex, Body mass index, GAF, duration of illness, CPZeq,
BPDeq, and DZPeq as independent variables
ANS activity
lnLF lnHF
Independent variable β P β P
Age −0.197 0.375 −0.015 0.938
Sex 0.252 0.086 0.237 0.063
Body mass index −0.024 0.880 0.047 0.733
GAF −0.004 0.978 0.046 0.724
Duration of illness −0.017 0.924 −0.157 0.300
CPZeq*1 −0.369 0.048*2 −0.415 0.011*3
BPDeq*4 −0.089 0.584 −0.259 0.070
DZPeq*5 −0.201 0.219 −0.151 0.284
*1The daily dose of antipsychotic drug was converted to approximate
chlorpromazine equivalent.
*2,3Significant difference (P < 0.05).
*4The daily dose of anticholinergic antiparkinsonian drug was converted to
approximate biperiden equivalent.
*5The daily dose of anxiolytic drug was converted to approximate diazepam
equivalent.control subjects. The LF component of HRV represents
both sympathetic and parasympathetic nerve activity,
the HF component represents almost entirely parasym-
pathetic nerve activity, and the LF/HF ratio represents
relative sympathetic nerve activity [22,31]. Thus, we
found decreased parasympathetic nerve activity, but not
decreased sympathetic nerve activity, in patients with
schizophrenia compared to healthy controls. Based on
HRV power spectral analysis, autonomic dysregulation
is a consistent finding in schizophrenia, regardless of
medication status [13-15,32]. Our present results are
concordant with those of previous studies [18,19,22,33].
Some researchers have suggested an association between
decreased ANS activity and the severity of schizophrenia.
These authors reported parasympathetic hypoactivity in
medication-free patients with schizophrenia [13,34,35]
and that parasympathetic nerve activity is significantly
decreased when the psychotic state is more pronounced
[15-17,36]. A few studies have suggested that suppression
of parasympathetic nerve activity is associated with dis-
turbances in cortical-subcortical circuits and other cen-
tral nervous system pathologies in schizophrenia [13,37].
However, patients in those studies were on medication or
had been treated with antipsychotic drugs 1 to 4 weeks
before ANS activity measurements. Interrupted or read-
ministered antipsychotic drugs could possibly have had
more or less of an effect on ANS activity in patients in
those studies.
In contrast, a few studies state that medication affects
ANS activity in patients with schizophrenia. Studies have
reported that some antipsychotic drugs, such as cloza-
pine, with wide-ranging receptor affinity profiles, show
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nerve activity [18,19] and that other antipsychotics
drugs, such as haloperidol, which are relatively free of
significant effects on neurotransmitter receptors except
dopamine receptors, have no significant effect on ANS
activity [19,38]. The results of those studies suggest that
the effects of antipsychotic drugs on ANS function are
derived from anticholinergic and antiadrenergic activity.
In the present study, levomepromazine and chlorpro-
mazine, which have potent anticholinergic and antiadre-
nergic effects, were commonly used, and many of our
subjects were treated with multiple antipsychotic drugs.
Considering the results of previous studies and recep-
tor affinity profiles, it is a consensus view that anti-
psychotic drugs have more or less of an effect on ANS
activity. However, there is little evidence to indicate the
dosage of antipsychotic drugs necessary to affect ANS
activity. We investigated the dose-dependent effect of
antipsychotic drugs on ANS activity. Our results suggest
the following. If the daily dose of antipsychotic drugs is
≤500 mg/day, ANS activity in patients with schizophre-
nia is not significantly lower than that in controls. If the
daily dose of antipsychotic drugs is 501 to 1000 mg/day,
antipsychotic drugs exert a large effect on ANS activity
and decrease ANS activity. If the daily dose of anti-
psychotic drugs is ≥1001 mg/day, antipsychotic drugs
exert a very large effect on ANS activity and decrease
ANS activity significantly. In short, the effect might be
large if the dose of antipsychotic drug is high. There was
a statistically significant difference in mean GAF scores
among three subgroups. However, the result of the mul-
tiple regression analysis showed that there was no asso-
ciation between the spectral components of HRV and
GAF score after adjustment for variables such as age,
sex, BMI, duration of illness, CPZeq, BPDeq, and DZPeq
(Table 3).
Multiple regression analysis of the schizophrenia
group showed a statistically significant association be-
tween daily dose of antipsychotic drugs and parasympa-
thetic nerve activity. However, there was no correlation
between ANS activity and daily dose of anticholinergic
antiparkinsonian or anxiolytic drugs. In the present
study, the anticholinergic antiparkinsonian drug dose
was 3.2 ± 1.5 mg/day (BPDeq). Anticholinergic antipar-
kinsonian drugs potentially affect ANS activity; however,
the effect might be small unless at a high dose. There
was also no association between ANS activity and the
severity of the disease or duration of illness. In addition,
multiple regression analysis showed that ANS activity
was not associated with age, although there was a statis-
tically significant difference in mean age between the pa-
tient group and the control group.
To summarize our results, we interpreted our findings
as follows. 1) Antipsychotic drugs decreased ANS activityin medicated patients with schizophrenia, presumably
mediated by the parasympathetic nervous system. 2) If
the antipsychotic drug dose was ≥501 mg/day, anti-
psychotic drugs had a dose-dependent effect on ANS ac-
tivity and decreased ANS activity significantly, at least, in
medicated patients. 3) Anticholinergic antiparkinsonian
drugs did not significantly affect ANS activity unless at a
high dose. 4) The severity of schizophrenia did not have
an effect on ANS activity.
The present study has some potential limitations. First,
although the patient sample size was greater than 200,
the number of subjects was still relatively small. Second,
we did not analyze the influence of each drug separately
because most of our subjects were treated with multiple
drugs. Third, because there were no medication-free
patients, it is unclear whether the pathomechanisms
and/or the severity of schizophrenia directly affect ANS
activity. Additional investigations are necessary to clarify
these issues.
Our present results suggest that antipsychotic drugs
exert a dose-dependent effect on ANS activity and de-
crease ANS activity significantly and that HRV power
spectral analysis, as a diagnostic measurement of ANS,
may allow for the identification of patients at high risk
for sudden cardiac death. Therefore, we suggest that low
ANS activity might be a biomarker for adverse effects of
antipsychotic drugs rather than severity of schizophre-
nia. Prospective studies will be aimed at carefully collect-
ing data from at-risk patients to elucidate the association
between subclinically decreased ANS activity and the oc-
currence of serious adverse effects. These investigations
will provide clinical evidence for HRV power spectral
analysis as a potential monitoring system to protect psy-
chiatric patients from severe adverse events such as fatal
ventricular arrhythmias.
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